The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Familial pancreatic cancer describes families with at least two first-degree relatives with pancreatic cancer that do not fulfil the criteria of other inherited tumor syndromes with increased risks of pancreatic cancer. Although much has been learned regarding the aggregation of pancreatic cancer in some families, the genetic basis for this familial aggregation is poorly understood. This study evaluated the prevalence of 10 Polish founder mutations in four genes among individuals from families with diagnosed familial pancreatic cancer syndrome and assessed their possible association with the familial pancreatic cancer (FPC) risk in Poland. Materials and Methods In this study, 400 FPC individuals and 4,000 control subjects were genotyped for founder mutations in BRCA1 (5382insC, 4153delA, C61G), CHEK2 (1100delC, IVS2+1G>A, del5395, I157T), NBS1 (657del5), and PALB2 (509_510delGA, 172_175delTTGT) genes. Results A statistically significant association was observed between the 172_175delTTGT mutation of the PALB2 gene and an increased risk of FPC syndrome (odds ratio [OR], 10.05; p=0.048). In addition, an increased risk of cancer was observed in the FPC family members with a BRCA1 mutation (OR, 6.72; p=0.006). Novel associations were found between the FPC family members with cancer and CHEK2mutations (OR, 2.26; p=0.008) with a noticeable contribution of the missense variant, I157T of CHEK2 (OR, 2.17; p=0.026). Conclusion The founder mutations in the genes, BRCA1, PALB2, and CHEK2, cause a small percentage of familial pancreatic cancer syndrome in the Polish population. Following confirmation in larger studies, these mutations can be added to the panel of genes to be tested in families with a diagnosis of FPC syndrome.
Abstract
Purpose Familial pancreatic cancer describes families with at least two first-degree relatives with pancreatic cancer that do not fulfil the criteria of other inherited tumor syndromes with increased risks of pancreatic cancer. Although much has been learned regarding the aggregation of pancreatic cancer in some families, the genetic basis for this familial aggregation is poorly understood. This study evaluated the prevalence of 10 Polish founder mutations in four genes among individuals from families with diagnosed familial pancreatic cancer syndrome and assessed their possible association with the familial pancreatic cancer (FPC) risk in Poland. Materials and Methods In this study, 400 FPC individuals and 4,000 control subjects were genotyped for founder mutations in BRCA1 (5382insC, 4153delA, C61G), CHEK2 (1100delC, IVS2+1G>A, del5395, I157T), NBS1 (657del5), and PALB2 (509_510delGA, 172_175delTTGT) genes. Results A statistically significant association was observed between the 172_175delTTGT mutation of the PALB2 gene and an increased risk of FPC syndrome (odds ratio [OR], 10.05; p=0.048). In addition, an increased risk of cancer was observed in the FPC family members with a BRCA1 mutation (OR, 6.72; p=0.006). Novel associations were found between the FPC family members with cancer and CHEK2mutations (OR, 2.26; p=0.008) with a noticeable contribution of the missense variant, I157T of CHEK2 (OR, 2.17; p=0.026). Conclusion The founder mutations in the genes, BRCA1, PALB2, and CHEK2, cause a small percentage of familial pancreatic cancer syndrome in the Polish population. Following confirmation in larger studies, these mutations can be added to the panel of genes to be tested in families with a diagnosis of FPC syndrome.
참고문헌 (22)
- Klein AP, "Familial pancreatic cancer", Cancer J, 7, pp.266~273 (2001)
- MacDermott RP, "Adenocarcinoma of the pancreas in four siblings", Gastroenterology, 65, pp.137~139 (1973)
- Lynch HT, "Familial pancreatic carcinoma in Jews", Fam Cancer, 3, pp.233~240 (2004)
- Gorski B, "Breast cancer predisposing alleles in Poland", Breast Cancer Res Treat, 92, pp.19~24 (2005)
- Cybulski C, "A deletion in CHEK2 of 5, 395 bp predisposes to breast cancer in Poland", Breast Cancer Res Treat, 102, pp.119~122 (2007)
- Cybulski C, "Clinical outcomes in women with breast cancer and a PALB2 mutation : a prospective cohort analysis", Lancet Oncol, 16, pp.638~644 (2015)
- Menkiszak J, "Hereditary ovarian cancer in Poland", Int J Cancer, 106, pp.942~945 (2003)
- Cybulski C, "CHEK2 is a multiorgan cancer susceptibility gene", Am J Hum Genet, 75, pp.1131~1135 (2004)
- Cybulski C, "A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer", J Med Genet, 43, pp.863~866 (2006)
- Zlowocka E, "Germline mutations in the CHEK2kinase gene are associated with an increased risk of bladder cancer", Int J Cancer, 122, pp.583~586 (2008)
- Teodorczyk U, "The risk of gastric cancer in carriers of CHEK2 mutations", Fam Cancer, 12, pp.473~478 (2013)
- Cybulski C, "NBS1 is a prostate cancer susceptibility gene", Cancer Res, 64, pp.1215~1219 (2004)
- Lener MR, "Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer", Int J Cancer, 139, pp.601~606 (2016)
- Slater EP, "PALB2 mutations in European familial pancreatic cancer families", Clin Genet, 78, pp.490~494 (2010)
- Mocci E, "PanGen-Fam : Spanish registry of hereditary pancreatic cancer", Eur J Cancer, 51, pp.1911~1917 (2015)
- Vasen H, "Benefit of surveillance for pancreatic cancer in highrisk individuals : outcome of long-term prospective follow-up studies from three European expert centers", J Clin Oncol, 34, pp.2010~2019 (2016)
- Zhou BB, "The DNA damage response : putting checkpoints in perspective", Nature, 408, pp.433~439 (2000)
- Matsuoka S, "Linkage of ATM to cell cycle regulation by the Chk2 protein kinase", Science, 282, pp.1893~1897 (1998)
- Vahteristo P, "A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer", Am J Hum Genet, 71, pp.432~438 (2002)
- Chehab NH, "Chk2", hCds1 functions as a DNA damage checkpoint in G(1)by stabilizing p53, 2000, pp.14, 278~288
- Suchy J, "CHEK2 mutations and HNPCC-related colorectal cancer", Int J Cancer, 126, pp.3005~3009 (2010)
- Bartsch DK, "Low frequency of CHEK2 mutations in familial pancreatic cancer", Fam Cancer, 5, pp.305~308 (2006)